著者

大山 武司 前川 正信 柏原 昇

出版者

泌尿器科紀要刊行会

雑誌

泌尿器科紀要 (ISSN:00181994)

巻号頁・発行日

vol.28, no.4, pp.493-497, 1982-04

---

We studied the data obtained by administering Tsumura Hachimijiogan to 28 impotent patients and 29 normal individuals. During two weeks of administration, we assessed the efficacy of the drug by examining the answers of the subjects to a questionnaire handed out before administration, the Cornell Medical Index (C.M.I.) and the results of the Yatabe-Guilford (Y-G) tests. We also measured blood testosterone, 17-KS and 17-OHCS, before and after administration to assess the influence of Hachimijiogan on hormone production. 1) Ability of erection: An increased ability of erection was observed in 65.4% of the impotent patients and an amelioration of morning erection in 50% of the patients. An increased ability of erection was observed in 36% of the control subjects, and an amelioration of morning erection in 24%. 2) Efficacy rate of Hachimijogan was 64% in the control group and 76.9% in the impotent group. The efficacy rate as observed by age was 100% for the control subjects who were over 40 years old; it was smallest for the control subjects in their thirties. However, little difference in the efficacy rate was observed with age in the impotent group. 3) Efficacy rate for problem groups: There was no difference between the efficacy rate for the problem groups in the C.M.I. and Y-G tests and the overall efficacy. 4) Efficacy rate by habitus: The drug was very effective for 71.4% of the impotent patients who had a slender build. 5) The side effects most frequently observed were gastroenteritic disorders. In three cases, drug administration was discontinued because of side effects. Side effects were observed at the highest percentage in pyknic subjects, appearing in more than half of them. 6) Blood testosterone, urinary 17-KS, 17-OHCS: There was no significant difference between the values obtained for the patients or control subjects before and after the administration of Hachimijiogan.

著者

田中 寛 加藤 禎一 柿木 宏介 西尾 正一 前川 正信 辻田 正昭 西島 高明 柏原 昇 甲野 三郎 早原 信行

出版者

泌尿器科紀要刊行会

雑誌

泌尿器科紀要 (ISSN:00181994)

巻号頁・発行日

vol.29, no.1, pp.p95-103, 1983-01

---

Cefmenoxime (CMX)について,基礎的ならびに臨床的検討を行った.1.健康成人4名に対しCMX250 mgをcross over法を用いて,筋注,静注および1時間の点滴静注の3方法で投与した.各投与法における最高血中濃度(時間),血中半減期はそれぞれ,筋注5.9±0.1 μg/ml(30分),1.41時間,静注11.1±1.2 μg/ml(15分),1.26時間,1時間の点滴静注12.4±1.4(点滴静注終了時)0.94時間であった(いずれもMean±S.E.).またCMXの投与後6時間までの尿中排泄率は,いずれも60~70%であった.2.急性単純性膀胱炎4例に対するCMXの有効率は100%であった.3.複雑性尿路感染症10例に対する有効率は70%であった.無効例はいずれもカテーテル留置例でPseudomonasが存続もしくは菌交代として出現したものであった.なお従来のcephalosporin系抗生剤に耐性のSerratiaが陰性化した.4. CMX投与による自覚的副作用は認められなかった.しかし一過性に軽度のtransaminaseの上昇が1例にみられたBasic and clinical studies were made on Cefmenoxime (CMX), a new cephalosporin antibiotic, and the following results were obtained. The serum concentration of CMX was examined in four healthy adults after administration of 250 mg of CMX by intramuscular injection, intravenous injection and one-hour intravenous drip infusion (cross over). In the case of intramuscular injection, the peak value of 5.9 micrograms/ml was obtained 30 minutes after administration, and the half-life in serum was 1.41 hours. In the case of intravenous drip infusion, injection, a concentration value of 11.1 micrograms/ml on the average was obtained after 15 minutes of administration, and the half-life in serum was 1.26 hours. In the case of intravenous drip infusion, the concentration was 12.4 micrograms/ml upon completion of drip infusion, and CMX disappeared from serum at a half-life of 0.94 hour. The urinary recovery up to 6 hours was from 60 to 70% in each The efficacy rate of this preparation was 100% for 4 cases of acute simple cystitis. The efficacy rate of CMX was 70% for 10 cases of complicated urinary tract infection; the 3 cases in which CMX was not effective were patients with a residual catheter and Pseudomonas persisting or appearing as superinfection. It was noted that Serratia, which was resistant to the conventional cephalosporin antibiotics, became negative. No subjective side effects due to the administration of this preparation were observed. As for abnormal laboratory findings, a slight and transient rise in transaminases was observed in one case. On the basis of the above-mentioned results, it was concluded that CMX is an effective preparation for the treatment of urinary tract infections.